Product Images Levetiracetam
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 11 images provide visual information about the product associated with Levetiracetam NDC 16714-355 by Northstar Rx Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1
The figure displays the Responder Rate in Study 1, which indicates a reduction of 250% from baseline. The percentage values range from 0% to 39.6%, with the statistically significant versus placebo. No other information is available for analysis.*
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 750 mg (500 Tablets Bottle) - levetiracetam fig10
Each tablet contains Levetiracetam USP and is manufactured by Aurobindo Pharma Limited for Northstar Rx LLC. The package contains 60 film-coated tablets with complete dosage recommendations in the package insert. The container comes with a child-resistant closure and should be stored at 20-25°C (68-77°F). Medication guides are available at 1-800-206-7821 or from the manufacturer's website. The product is made in India and has a code for identification purposes.*
Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2
Figure 2 shows the Responder Rate in Study 2, indicating a 250% reduction from baseline in Period A. The percentage of patients who responded to treatment is shown on the y-axis while the placebo and two different doses of levetiracetam (1000mg/day and 2000mg/day) are marked on the x-axis. The percentage of responders is highest for the 2000mg/day dosage (35.2%) followed by the 1000mg/day dosage (30%) and lowest for the placebo (5%). It is also mentioned that the difference between the percentage of responders for the 2000mg/day dosage and the placebo is statistically significant.*
Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3
This is a figure showing the responder rate (>50% reduction from baseline) in Study 3. It compares the results of a placebo group of 104 people with a group of 180 people taking 3000 mg/day of Levetiracetam. The Levetiracetam group had a responder rate of 45%, which was statistically significant compared to the 14.4% responder rate in the placebo group.*
Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4
The text describes a figure showing the Responder Rate percentage of a study that compared the effects of a drug, Levetiracetam, versus a placebo. The study shows that subjects who received Levetiracetam had a statistically significant response rate (a 50% reduction from baseline) than those who received placebo. The graph shows the percentages of the responder rate for both groups. The text indicates that the responder rate for the placebo group was 44.6%, while for the Levetiracetam group, it was 45%.*
Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5
The figure shows the responder rate for all patients aged 1 month to under 4 years old in Study 5. The responder rate indicates a reduction of over 50% from the baseline. The graph displays the percentage of patients on the Y-axis and the placebo and levetiracetam groups on the X-axis. The levetiracetam group had a responder rate of 19.6%, which was statistically significant compared to the placebo group (N=51 for the placebo and N=58 for the levetiracetam group).*
Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6
The text describes a graph (Figure 6) that shows the responder rate in reducing PGTC seizure frequency per week in Study 7. The graph indicates the percentage of patients who responded to treatment (reducing seizure frequency by 250% from baseline) for placebo and Levetiracetam (N=79) groups. The Levetiracetam group had a higher responder rate (72.2%) compared to the placebo group (45.2%) and the difference was statistically significant.*
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 250 mg (500 Tablets Bottle) - levetiracetam fig7
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg (500 Tablets Bottle) - levetiracetam fig8
Each film-coated tablet contains 500 mg of Levetiracetam USP. This medication is manufactured by Aurobindo Pharma Limited in Hyderabad, India and distributed by Northstar Rx LLC in Memphis, TN. The recommended dosage is available in the package insert. The tablets are stored in USP controlled room temperature and come in a child-resistant container. The medication guide is available separately and can be obtained through the Northstar Rx LLC website or by calling their customer service line.*
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 750 mg (500 Tablets Bottle) - levetiracetam fig9
This is a medication called Levetiracetam. Each film-coated tablet contains 750mg of the medication. The manufacturer is Northstar Rx LLC based in Memphis, TN. The usual dosage is available in the package insert from the manufacturer Aurobindo Pharma Limited. The medication is stored at 20° to 25°C (68° to 77°F), excursions permitted to 15° o 30°C (59° to 86°F) [see USP Controlled Room Temperature]. The medication is available in a container with a child-resistant closure. The NDC number is 16714-356-02. The medication guide is available at www.northstarrxlic.com/products or by calling 1-800-206-7821. There are 500 tablets in the container. There is additional text including a product code and printing information.*
Chemical Structure - levetiracetam str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.